Dry Eye Disease Market Outlook 2034 - Competitive Landscape, Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Dry Eye Disease Market Summary
In 2023, the Dry Eye Disease (Dry Eye Disease) market across the 7MM was valued at approximately USD 3.76 billion, with the US leading at USD 2.74 billion and roughly 22.5 million diagnosed cases. Both prevalence and market size are expected to increase through 2034.
• Japan: ~2.3M males and ~8.3M females affected in 2023, with numbers projected to rise.
• UK: ~2.8M mild, ~1.3M moderate, and ~2.0M severe cases in 2023, all anticipated to grow.

The current Dry Eye Disease treatment landscape includes VEVYE, TYRVAYA, EYSUVIS, CEQUA, off-label therapies, and eye drops, with future growth likely driven by emerging therapies between 2024-2034. Key Dry Eye Disease companies developing novel treatments include Palatin Technologies, Aldeyra Therapeutics, ReGenTree/RegeneRx, Mimetogen, Alcon/Aerie, BRIM Biotechnology, Seikagaku, Mitotech, Senju Pharmaceutical, Sylentis/PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll/Daewoong, Redwood Pharma, OKYO Pharma, Glaukos, Oculis, and others.

DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034" delivers a comprehensive overview of Dry Eye Disease, analyzing historical and projected epidemiology, treatment trends, therapy-wise market share, and market size from 2020 to 2034 across the US, EU5 (Germany, Spain, Italy, France, UK), and Japan. The report also examines treatment algorithms, key market drivers, barriers, and unmet needs, enabling identification of growth opportunities and evaluation of the market's potential.

Explore DelveInsight's in-depth analysis of the Dry Eye Disease market, including epidemiology trends, emerging therapies, and competitive landscape across the 7MM - https://www.delveinsight.com/report-store/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Developments and Studies in Dry Eye Disease:
• In June 2025, Aldeyra Therapeutics has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for reproxalap, an investigational treatment aimed at addressing the signs and symptoms of dry eye disease (DED).
• May 2025: AbbVie initiated a study evaluating safety, tolerability, and pharmacokinetics of AGN-242428 and AGN-231868 in Stage 1, progressing to Stage 2 to assess efficacy in treating Dry Eye Disease.
• May 2025: University of Waterloo started a study to measure comfort and dryness in symptomatic contact lens wearers using Xiidra (lifitegrast 5%) for 12 weeks.
• In April 2025, Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on developing first-in-class therapies targeting the melanocortin receptor system, has announced updated responder analysis results from its pivotal Phase 3 MELODY-1 trial. This study assessed the safety and efficacy of PL9643 compared to placebo in treating dry eye disease (DED). The latest data further reinforce PL9643's clinical potential, demonstrating statistically significant complete symptom resolution across multiple endpoints-an outcome not achieved by any currently approved DED treatments-highlighting its promise in addressing a key unmet need.
• February 2025: Cambium Bio received FDA approval for Phase III clinical trials of elate ocular for moderate-to-severe Dry Eye Disease.
• January 2024: Alcon announced successful Phase III results for AR-15512 in COMET-2 and COMET-3 trials, planning an NDA submission mid-2024.
• January 2024: Stuart Therapeutics commenced a Phase III trial of vezocolmitide (ST-100) for Dry Eye Disease.

Gain actionable insights on market size, forecasted trends, and pipeline therapies to inform your business and R&D strategies in the Dry Eye Disease domain - https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dry Eye Disease Market Insights:
• Estimated total diagnosed Dry Eye Disease cases in the 7MM in 2023 were ~54.7 million.
• The US held the largest share (~41%), followed by the UK (~6.1M) and Germany (~5M); Spain had the lowest (~2M).
• Females are more affected than males, with a growing gap expected by 2034.

Dry Eye Disease Overview
Dry Eye Disease (Dry Eye Disease), or keratoconjunctivitis sicca, is a multifactorial condition marked by inadequate tear production or excessive tear evaporation, causing ocular surface damage and symptoms such as dryness, irritation, redness, burning, and blurred vision. Contributing factors include age, hormones, autoimmune diseases (e.g., Sjögren's syndrome), prolonged screen use, environmental conditions, medications, and Meibomian gland dysfunction.
Dry Eye Disease Diagnosis and Management:
Dry Eye Disease diagnosis involves a detailed eye examination, including tear film assessment, Schirmer's test, TBUT, and ocular surface staining. Management strategies focus on symptom relief and underlying causes, including artificial tears, anti-inflammatory medications (cyclosporine, lifitegrast), punctal plugs, lifestyle modifications, and advanced therapies such as intense pulsed light (IPL) and autologous serum drops.

Access detailed evaluations of key players, therapy uptake, and clinical trial progress to stay ahead in the competitive Dry Eye Disease landscape - https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dry Eye Disease Market Outlook:
The Dry Eye Disease market is poised for expansion with potential launches of therapies such as RGN-259, Tavilermide (MIM-D3), and AR-15512. The US dominated the market in 2023 (~73% of the 7MM), with the UK leading in Europe (USD 232M) and Spain at the lowest share (~USD 80M). Emerging therapies including MC2-03 (MC2 Therapeutics) and PL9643 (Palatin Technologies) are expected to reshape the market landscape.

Understand the Dry Eye Disease prevalence, treatment patterns, and market opportunities across the US, EU5, and Japan to target your investments effectively - https://www.delveinsight.com/report-store/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dry Eye Disease Epidemiology:
• 7MM Dry Eye Disease diagnosed prevalence: ~54.7M in 2023.
• US: 41% of cases; UK: ~6.1M; Germany: ~5M; Spain: ~2M; Japan: 19%.
• Higher prevalence in females (~13M) vs. males (~9.4M) in the US.
• Mild cases dominate (~11.2M), followed by severe (~4.5M).

Dry Eye Disease Market Drivers:
• Rising prevalence and patient pool
• Lifestyle and environmental factors
• Unmet medical needs
• Technological advancements in treatment
• Pipeline innovation with emerging therapies
• Increasing awareness and diagnosis

Dry Eye Disease Market Barriers:
• Limited efficacy of current therapies
• High treatment costs
• Poor patient compliance
• Under diagnosis and misdiagnosis
• Competition from generics and OTC products
• Regulatory and clinical challenges

Discover unmet needs, market drivers, and innovative therapies in development to shape your strategic decisions and maximize ROI in the Dry Eye Disease market - https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dry Eye Disease Competitive Landscape:
Dry Eye Disease Drugs Uptake & Pipeline:
• Reproxalap (Aldeyra/AbbVie): Positive late-phase trial results, strong safety profile.
• Tivanisiran (Sylentis/PharmaMar): siRNA targeting TRPV1; Phase III FYDES trial successful.
• Tavilermide (MIM-D3): TrkA receptor agonist; Phase II/III efficacy consistent.
• AR-15512 (Alcon/Aerie): TRPM8 agonist; Phase III success, NDA submission expected 2024.
• RP101 (Redwood Pharma): Hormonal therapy for postmenopausal women; Phase II positive, asset planned for auction.

Emerging Dry Eye Disease Drugs Under Different Phases of Clinical Development Include:
• Qi 401: Quorum Innovations
• SER-114: Serentrix
• iVIEW 1001: IVIEW Therapeutics
• TJO-083: Taejoon Pharmaceutical
• SY-201: Seinda Pharmaceutical
• INV-102: Invirsa
• GLH8NDE: GL Pharm Tech Corporation
• SHJ 002: Dreamhawk Vision Biotech, Inc
• A197: Aramis Biosciences
• K-161: Kowa Company
• AR-15512: Alcon
• HL036: HanAll Biopharma
• SI-614: Seikagaku Corporation
• NOV03: Novaliq GmbH
• CyclASol: Novaliq GmbH

Get a comprehensive view of leading Dry Eye Disease companies, their marketed drugs, and emerging therapies in clinical development to identify collaboration, licensing, and investment opportunities - https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Dry Eye Disease Companies:
Palatin Technologies, Aldeyra Therapeutics, ReGenTree/RegeneRx, Mimetogen, Alcon/Aerie, BRIM Biotechnology, Seikagaku, Mitotech, Senju Pharmaceutical, Sylentis/PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll/Daewoong, Redwood Pharma, AxeroVision, OKYO Pharma, Glaukos, Oculis, and others.

Scope of the Dry Eye Disease Market Report:
• Study period: 2020-2034
• Coverage: 7MM (US, EU5, Japan)
• Key therapies: PL9643, NOV03, CyclASol, MC2-03, others
• Assessment: Current and emerging therapies, market dynamics, competitive intelligence, unmet needs, KOL and analyst insights

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.